EPL 1410
Alternative Names: EPL1410Latest Information Update: 28 May 2022
At a glance
- Originator Emcure Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in India (PO)
- 21 Apr 2018 Preclinical trials in Cancer in India (PO)
- 21 Apr 2018 Pharmacokinetics and pharmacodynamics data from preclinical trials presented at the presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)